NASDAQ: CLSD - Clearside Biomedical, Inc.

Lønnsomhet i seks måneder: -25.2%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan Clearside Biomedical, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Clearside Biomedical, Inc.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc.

flere detaljer
has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2016-06-02
ISIN US1850631045
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://clearsidebio.com
Цена ао 1.02
Prisendring per dag: -7.77% (1.03)
Prisendring per uke: -5.47% (1.005)
Prisendring per måned: +5.56% (0.9)
Prisendring over 3 måneder: 0% (0.95)
Prisendring over seks måneder: -25.2% (1.27)
Prisendring per år: -37.91% (1.53)
Prisendring over 3 år: -60.58% (2.41)
Prisendring over 5 år: -63.04% (2.57)
Prisendring siden begynnelsen av året: 0% (0.95)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 7.81 1
P/BV -4.04 0
P/E 0 0
EV/EBITDA -3.16 0
Total: 3.75

Effektivitet

Navn Betydning Karakter
ROA, % -95.49 0
ROE, % 204.15 10
Total: 3.33

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -1.74 10
Total: 7.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 273.91 10
Lønnsomhet Ebitda, % -23.9 0
Lønnsomhet EPS, % -34.35 0
Total: 2.2
Flere detaljer

Institusjoner Volum Dele, %
Vanguard Group Inc 2176316 2.91
Carmignac Gestion 2132744 2.85
Blackrock Inc. 759743 1.02
Geode Capital Management, LLC 490690 0.66
Renaissance Technologies, LLC 384689 0.51
State Street Corporation 193363 0.26
Bridgeway Capital Management, Inc. 175600 0.24
First Manhattan Company 175000 0.23
Johnson & Johnson 169629 0.23
Morgan Stanley 144434 0.19

ETFDele, %Lønnsomhet for året, %Utbytte, %
iShares Micro-Cap ETF 0.02367 17.09 1.54048
0.0217.091.54



Veileder Stillingstittel Betaling Fødselsår
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. President, CEO & Director 836.15k 1952 (73 år)
Mr. Charles A. Deignan Chief Financial Officer 568.68k 1964 (61 år)
Ms. Jenny R. Kobin Head of Investor Relations N/A 1967 (58 år)
Mr. Rick McElheny Senior Vice President of Corporate Development & Alliance Management N/A
Mr. Rafael V. Andino Senior Vice President of Engineering & Manufacturing N/A 1965 (60 år)
Ms. Susan L. Coultas Ph.D. Chief Clinical Officer N/A
Mr. Leslie B. Zacks Secretary N/A 1969 (56 år)
Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. Chief Medical Officer

Adresse: United States, Alpharetta. GA, 900 North Point Parkway - åpne i Google maps, åpne Yandex-kart
Nettsted: https://clearsidebio.com